Sen. Kennedy (D-Mass.) price & promotion investigations
Executive Summary
Senate Labor & Human Resources Committee may hold two days of hearings by early summer as a follow-up to the inquiries about marketing practices sent to industry last summer. In one-two punch, the first day is expected to focus on pharmaceutical marketing and promotion; the second on prices. The two-day format was very successful for Kennedy during his big investigation of the pharmaceutical industry in the mid-1970's. The chief investigator for the drug hearings is Walter Sheridan, one of the key investigators from the earlier round and a major player in the Jimmy Hoffa investigations in the early 1960's. Kennedy's staff is playing the dates and subjects of the hearings close to the vest. At his best, Kennedy used to spring the hearings, witness lists and questions on short notice.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.